Adjuvant CDK4/6 inhibition in early-stage HR-positive breast cancer | Ruth O'Regan

preview_player
Показать описание
Ruth O'Regan comments on the monarchE trial of abemaciclib and the PENELOPE-B and PALLAS trials of palbociclib investigating CDK4/6 inhibitor therapy in the adjuvant, hormone receptor-positive, early-stage breast cancer setting.
  1. Medicine Matters oncology
  2. Medicine
  3. Oncology
  4. Cancer
Рекомендации по теме
Adjuvant CDK4/6 inhibition 0:06:36

Adjuvant CDK4/6 inhibition in early-stage HR-positive breast cancer | Ruth O'Regan

ESMO Daily Reporter 0:21:47

ESMO Daily Reporter Talk: The role of CDK4/6 inhibitors in the early stage of #breastcancer.

CDK4/6 inhibitors in 0:02:22

CDK4/6 inhibitors in early stage HR+/HER2- disease

Adjuvant CDK4/6 Inhibition: 0:03:23

Adjuvant CDK4/6 Inhibition: When it Will Become Routine

Unmet needs and 0:02:06

Unmet needs and CDK4/6 inhibitors in HR+/HER2- early breast cancer

Adjuvant CDK4 and 0:58:22

Adjuvant CDK4 and 6 Inhibition to Prevent Recurrences in High-Risk HR+/HER2- Early Breast Cancer

monarchE and PALLAS: 0:05:47

monarchE and PALLAS: A tale of two CDK4/6 inhibitors | George Sledge Jr

The benefits of 0:03:35

The benefits of adjuvant CDK4/6 and PARP inhibition in breast cancer

What is the 0:05:07

What is the role of CDK4/6 inhibitors in early breast cancer?

monarchE: adjuvant abemaciclib 0:01:12

monarchE: adjuvant abemaciclib in HR+ breast cancer

Breast cancer at 0:06:15

Breast cancer at ESMO 2020: CDK4/6 inhibitors and checkpoint inhibitors

Unmet needs in 0:01:11

Unmet needs in the use of CDK4/6 inhibitors in early-stage HR+/HER2- breast cancer

Current and future 0:02:45

Current and future CDK4/6 inhibitors in high-risk early-stage HR+ breast cancer

Emerging evidence on 0:18:07

Emerging evidence on the role of CDK4/6 inhibitors in early BC

Dr. Ellis on 0:01:24

Dr. Ellis on Adjuvant CDK4/6 Inhibition in HR-Positive Breast Cancer

Final results from 0:03:30

Final results from PALLAS: adjuvant palbociclib in HR+/HER2- early breast cancer

ESMO 2020 Expert 0:05:32

ESMO 2020 Expert Video Report on CDK4 6i in the adjuvant treatment of breast cancer

Biomarkers to help 0:01:04

Biomarkers to help predict response to CDK4/6 inhibitors

CDK4/6 Inhibitors in 0:07:40

CDK4/6 Inhibitors in the First-line Treatment Setting

Remaining questions on 0:01:12

Remaining questions on the use of frontline CDK4/6 inhibitors + endocrine therapy

Future Directions: CDK4/6 0:04:52

Future Directions: CDK4/6 Inhibitors in Breast Cancer

CDK 4/6 Inhibitors 0:02:19

CDK 4/6 Inhibitors for Patients with Recurrent ER+/HER2- Breast Cancer: 2023 Best of Breast

CDK4/6 Inhibitors & 0:04:17

CDK4/6 Inhibitors & Endocrine Therapy in Breast Cancer

CDK 4/6 inhibition 0:26:40

CDK 4/6 inhibition in early breast cancer By Dr. Ahmed Saadeddin 18-6-2021 (Day1)